Beta Bionics Inc.
BBNX evidence brief
What we can confirm
- BioSniper Score:
- 4.6 / 10
- Market Cap:
- $1.13B
- Next Catalyst:
- Earnings · Oct 27, 2026
What it means
What to watch
Prepared research question
What matters most for BBNX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BBNX
Beta Bionics Inc. (BBNX) is a publicly traded company developing advanced diabetes management solutions, including the iLet pump and the Mint patch pump, with a focus on Type 1 diabetes and early-stage bihormonal and patch pump technologies.
Key risk: Operating losses
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 catalyst for Beta Bionics Inc..
Beta Bionics Inc. (BBNX) is a publicly traded company developing advanced diabetes management solutions, including the iLet pump and the Mint patch pump, with a focus on Type 1 diabetes and early-stage bihormonal and patch pump technologies.
- Cash & equivalents of $44.3M as of 2026-06-30 [sec]
- Total revenue of $32.0M and net loss of -$23.4M as of 2026-06-30 [sec]
- Shareholders' equity of $256.4M as of 2026-06-30 [sec]
- Mint patch pump FDA-cleared for 1Q27 launch [news · 2026-09-17]
- Company expects cash runway through first half of 2028 [sec_mda · as of 2026-07-29]
What works
- Cash runway projected through first half of 2028 based on current operating plans [sec_mda · as of 2026-07-29]
- Mint patch pump has received FDA clearance, targeting a 1Q27 launch [news · 2026-09-17]
- Company is investing in disruptive technologies including a patch pump and a first-of-its-kind bihormonal system [sec_mda · as of 2026-04-21]
What to weigh
- Company has incurred significant operating losses since inception and expects to continue incurring losses for the foreseeable future [sec_mda · as of 2026-07-29]
- Net loss of -$23.4M as of 2026-06-30 [sec]
- Patch pump (Mint) commercialization timeline was updated in May 2026, indicating potential delays [news · 2026-05-21]
- Sales guidance lowered and margin dilution risks noted in analyst reports [news · 2026-09-17]
From the filings
Quoted directly from source documents.
Cash runway through first half of 2028
“we believe that our existing cash, cash equivalents and short-term and long-term investments, as well as cash generated from sales of our products, will be sufficient to fund our projected operating expenses and capital expenditure requirements through the first half of 2028”
SEC MD&A · July 29, 2026
Mint patch pump FDA-cleared for 1Q27 launch
“Mint patch pump FDA-cleared for 1Q27, boosting diabetes platform growth despite 2026 deferral”
News · September 17, 2026
Company expects continued operating losses
“We expect to incur significant expenses and operating losses for the foreseeable future as we advance the commercialization of our iLet, including future development of Mint, our patch pump, and the bihormonal system of the iLet”
SEC MD&A · July 29, 2026
Catalyst timeline
- 2026-10-27 · Earnings — Beta Bionics to Announce Third Quarter 2026 Financial Results — Release of Q3 2026 financial results after market close; will provide updated revenue, net loss, and cash position.
Risks & what to watch (4)›
Key risks
- Operating losses — Significant operating losses since inception; expects losses to continue [sec_mda · as of 2026-07-29]
- Pipeline delays — Mint patch pump commercialization timeline updated in May 2026, indicating potential delays [news · 2026-05-21]
- Margin dilution — Analyst reports note margin dilution risks and lowered sales guidance [news · 2026-09-17]
- Geopolitical/macroeconomic risks — Tariffs, trade measures, bank failures, geopolitical tensions may impact capital access [sec_mda · as of 2026-07-29]
What to watch
- Third quarter 2026 financial results to be announced on October 27, 2026 [catalyst]
- Mint patch pump launch in 1Q27 and its commercial uptake [news · 2026-09-17]
- Progress of the bihormonal iLet system and patch pump development [sec_mda · as of 2026-04-21]
- Cash runway and ability to fund operations through first half of 2028 [sec_mda · as of 2026-07-29]
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 2, 2026 · How we verify sources →
Run Beta Bionics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Beta Bionics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.14 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~14d
0 buys · 14 sells (180d)
Catalysts
Financials
Short Interest
as of May 20, 2026- % of float
- 14.0%
- Days to cover
- 5.1
- Shares short
- 6,194,778
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BBNX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Beta Bionics Inc.?
Beta Bionics Inc. (BBNX) is a publicly traded company developing advanced diabetes management solutions, including the iLet pump and the Mint patch pump, with a focus on Type 1 diabetes and early-stage bihormonal and patch pump technologies.
What is Beta Bionics Inc.'s next catalyst?
Beta Bionics Inc.'s next tracked catalyst is a Earnings event — "Earnings: Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026" — expected October 27, 2026.
Who is the CEO of Beta Bionics Inc.?
Mr. Sean T. Saint PE is the chief executive officer of Beta Bionics Inc. (BBNX).
Where is Beta Bionics Inc. headquartered?
Beta Bionics Inc. (BBNX) is headquartered in Irvine, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.